Results 11 to 20 of about 12,817 (217)

The effects of NS5A inhibitors on NS5A phosphorylation, polyprotein processing and localization

Journal of General Virology, 2011
Hepatitis C virus (HCV) non-structural protein 5A (NS5A) is a multi-functional protein that is expressed in basally phosphorylated (p56) and in hyperphosphorylated (p58) forms. NS5A phosphorylation has been implicated in regulating multiple aspects of HCV replication. We recently reported the identification of a class of compounds that potently inhibit
Dike, Qiu, Julie A, Lemm, Donald R, O'Boyle, Jin-Hua, Sun, Peter T, Nower, Van, Nguyen, Lawrence G, Hamann, Lawrence B, Snyder, Daniel H, Deon, Edward, Ruediger, Nicholas A, Meanwell, Makonen, Belema, Min, Gao, Robert A, Fridell   +13 more
openaire   +3 more sources

NS5A Inhibitors

Current Hepatitis Reports, 2012
As a result of rapid advance medicinal chemistry, the time frame 2011–2012 has been an exciting one that has witnessed the release of the first direct acting antiviral agents (DAA). Multiple enzymatic and protein regions of the virus can serve as targets for these new drugs. One of the newest and most promising of these targets is the NS5A protein. The
Christopher O’Brien, Nicholas Agresti
openaire   +2 more sources

Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052 [PDF]

Journal of Virology, 2011
ABSTRACT BMS-790052, targeting nonstructural protein 5A (NS5A), is the most potent hepatitis C virus (HCV) inhibitor described to date. It is highly effective against genotype 1 replicons and also displays robust genotype 1 anti-HCV activity in the clinic (M. Gao et al., Nature 465:96-100, 2010).
Robert A, Fridell, Dike, Qiu, Lourdes, Valera, Chunfu, Wang, Ronald E, Rose, Min, Gao   +5 more
openaire   +3 more sources

Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent.

PLoS ONE, 2015
Ledipasvir, a direct acting antiviral agent (DAA) targeting the Hepatitis C Virus NS5A protein, exhibits picomolar activity in replicon cells. While its mechanism of action is unclear, mutations that confer resistance to ledipasvir in HCV replicon cells ...
Hyock Joo Kwon, Weimei Xing, Katie Chan, Anita Niedziela-Majka, Katherine M Brendza, Thorsten Kirschberg, Darryl Kato, John O Link, Guofeng Cheng, Xiaohong Liu, Roman Sakowicz   +10 more
doaj   +2 more sources

Drug resistant variants of hepatitis C virus genotype 1b in Russia: analysis of aminoacid substitutions in NS5a and core proteins [PDF]

Журнал инфектологии, 2018
Aim. To determine the prevalence of amino acid substitutions in hepatitis C virus NS5a and core proteins which are associated with resistance to direct-acting antivirals and interferon in genotype 1b (HCV-1b) strains circulating in Russia.
V. S. Kichatova, A. A. Karlsen, O. V. Isaeva, S. A. Solonin, E. Yu. Malinnikova, K. K. Kyuregyan, M. I. Mikhailov   +6 more
doaj   +2 more sources

Recombinant HCV Variants With NS5A From Genotypes 1–7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α

Gastroenterology, 2011
Heterogeneity in the hepatitis C virus (HCV) protein NS5A influences its sensitivity to interferon-based therapy. Furthermore, NS5A is an important target for development of HCV-specific inhibitors. We aimed to develop recombinant infectious cell culture systems that express NS5A from isolates of the 7 major HCV genotypes, and determining their ...
Scheel, Troels K H, Gottwein, Judith M, Mikkelsen, Lotte S, Jensen, Tanja B, Bukh, Jens   +4 more
openaire   +4 more sources

Should NS5A inhibitors serve as the scaffold for all-oral anti-HCV combination therapies?

Hepatic Medicine: Evidence and Research, 2015
Sujit V Janardhan, Nancy S Reau Center for Liver Diseases, Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago, Chicago, IL, USA Abstract: Chronic hepatitis C virus (HCV) infection represents a global ...
Janardhan SV, Reau NS
doaj   +1 more source

Synergistic Activity of Combined NS5A Inhibitors [PDF]

Antimicrobial Agents and Chemotherapy, 2016
ABSTRACT Daclatasvir (DCV) is a first-in-class hepatitis C virus (HCV) nonstructural 5A replication complex inhibitor (NS5A RCI) that is clinically effective in interferon-free combinations with direct-acting antivirals (DAAs) targeting alternate HCV proteins.
Donald R, O'Boyle, Peter T, Nower, Min, Gao, Robert, Fridell, Chunfu, Wang, Piyasena, Hewawasam, Omar, Lopez, Yong, Tu, Nicholas A, Meanwell, Makonen, Belema, Susan B, Roberts, Mark, Cockett, Jin-Hua, Sun   +12 more
openaire   +2 more sources

Comparative Analysis of Hepatitis C Virus NS5A Dynamics and Localization in Assembly-Deficient Mutants

Pathogens, 2021
The hepatitis C virus (HCV) life cycle is a tightly regulated process, during which structural and non-structural proteins cooperate. However, the interplay between HCV proteins during genomic RNA replication and progeny virion assembly is not completely
Laura Riva, Corentin Spriet, Nicolas Barois, Costin-Ioan Popescu, Jean Dubuisson, Yves Rouillé   +5 more
doaj   +1 more source

Inhibitors of NS5A for Treatment of HCV Infection [PDF]

ACS Medicinal Chemistry Letters, 2013
Inhibitors of NS5A for Treatment of HCV Infection Jean-Francois Brazeau and Gerard Rosse* Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States Adjunct Associate Professor, Department of Pharmacology and Physiology, College of Medicine, Drexel University, New College Building, 245 North 15th ...
Jean-Francois, Brazeau, Gerard, Rosse
openaire   +2 more sources